Skip to main content
. 2010 May 27;12(3):R104. doi: 10.1186/ar3037

Table 1.

Patient characteristics according to the presence of any pulmonary function abnormalities

Characteristic No PFT abnormalities (n = 114) PFT abnormalities (n = 45) P value
Age (years) 61 ± 7.7 63 ± 9.9 0.14
Male gender 41 (36) 21 (47) 0.21
Caucasian 99 (87) 37 (82) 0.46
Body mass index (kg/m2) 29 ± 5.0 28 ± 5.5 0.12
Ever smoker 63 (55) 29 (64) 0.29
Current smoker 9 (7.9) 10 (22) 0.012
Reported lung disease 13 (11) 17 (38) < 0.001
 Emphysema 2 (1.8) 8 (18) < 0.001
 Asthma 12 (11) 8 (18) 0.22
 Rheumatoid lung disease 0 (0) 2 (4.7) 0.07
CAC > 100 34 (30) 19 (42) 0.14
RA characteristics
 RA duration (years) 9.9 (5.6 to 18) 11 (7.1 to 23) 0.16
 RF seropositive 64 (56) 35 (78) 0.011
 Anti-CCP seropositive 67 (59) 37 (84) 0.003
 DAS28 (units) 3.1 (2.4 to 3.7) 3.1 (2.4 to 4.2) 0.74
 HAQ (units) 0.75 (0.13 to 1.5) 0.88 (0.13 to 1.5) 0.48
 Modified Sharp Score (units) 41 (12 to 99) 56 (25 to 140) 0.098
 Current prednisone 35 (31) 23 (51) 0.018
 Current nonbiologic DMARDs 99 (88) 38 (84) 0.60
 Current biologic DMARDs 55 (49) 20 (44) 0.63
Reported pulmonary symptoms
 Any reported symptoms 41 (36) 26 (58) 0.012
 Any cough 19 (17) 16 (36) 0.010
 Any phlegm 22 (19) 16 (36) 0.030
 Any wheezing 17 (15) 18 (42) 0.001
 Any breathlessness 18 (16) 15 (33) 0.014

Data expressed as mean ± standard deviation, n (%) or median (interquartile range). CAC, coronary artery calcium; CCP, cyclic citrullinated peptide; DAS28, RA Disease Activity Score in 28 joints; DMARDs, disease-modifying antirheumatic drugs; PFT, pulmonary function test; RA, rheumatoid arthritis; RF, rheumatoid factor.